Orphazyme: Top-line data in NPC looks promising

Research Note

2018-09-28

08:51

Orphazyme has reported top-line results for the NPC Phase II/III trial, showing a treatment benefit of arimoclomol over placebo at 12 months.

MS

Mathias Spinnars

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.